{"preliminary_commentary":{"by_channel":{"x_thread":14,"podcast":6,"youtube":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04083976\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"RAGNAR","nct_id":"NCT04083976","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ragnar-nct04083976. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"RAGNAR","arms":[{"description":"Participants with fibroblast growth factor receptor (FGFR) mutations and FGFR gene fusions will receive a dose of erdafitinib oral tablets until disease progression, intolerable toxicity, withdrawal of consent, decision by the investigator to discontinue treatment, or end of data collection timepoint if there is clinical benefit in the opinion of the investigator, has been achieved.","label":"Erdafitinib","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-02-28","type":"ACTUAL"},"conditions":["Advanced Solid Tumor"],"enrollment":{"count":316,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Erdafitinib","otherNames":["JNJ-42756493"],"type":"DRUG"}],"last_update":"2026-09-17","lead_sponsor":"Janssen Research & Development, LLC","official_title":"A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-12-04","type":"ACTUAL"},"primary_outcomes":[{"measure":"Broad Panel and Pediatric Cohorts: Objective Response Rate (ORR) Based on Response Assessment in Neuro-Oncology (RANO) as Assessed by Independent Review Committee (IRC)","timeFrame":"Baseline (Cycle 1 Day 1 [each cycle of 21 days]) up to 4 years"},{"measure":"Core Panel Cohort: Objective Response Rate (ORR) Based on Response Assessment in Neuro-Oncology (RANO) as Assessed by Independent Review Committee (IRC)","timeFrame":"Baseline (Cycle 1 Day 1 [each cycle of 21 days]) up to 4 years"}],"references":[{"citation":"Carranza O, Pant S, Schuler M, Witt O, Geoerger B, Loriot Y, Farouk Sait S, Arnold D, Dal Molin GZ, Lugowska I, Winter H, Baldini C, Corassa M, Thomas S, Crow L, Xia Y, Triantos S, Sweiti H, Reardon DA. Erdafitinib in Patients With Advanced Solid Tumors With FGFR Alterations (RAGNAR): Results of Tumor-Specific Analyses and Secondary Cohorts. JCO Precis Oncol. 2026 Jul;10(7):e2501094. doi: 10.1200/PO-25-01094. Epub 2026 Jul 15.","pmid":"42456086","type":"DERIVED"},{"citation":"Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, Tabernero J, Reardon DA, Massard C, Minchom A, Lugowska I, Carranza O, Arnold D, Gutierrez M, Winter H, Stuyckens K, Crow L, Najmi S, Hammond C, Thomas S, Santiago-Walker A, Triantos S, Sweiti H, Loriot Y; RAGNAR Investigators. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol. 2023 Aug;24(8):925-935. doi: 10.1016/S1470-2045(23)00275-9.","pmid":"37541273","type":"DERIVED"}],"start_date":{"date":"2019-11-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations","url":"https://clinicaltrials.gov/study/NCT04083976"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ragnar-nct04083976"}